Medication-related osteonecrosis of the jaw: A cross-sectional study on the prevalence of cutaneous manifestations and the primary care physician's role in its early diagnosis
Bone-modifying agents (BMA), such as nitrogen-containing bisphosphonates (N-BP) s)(e.g., zoledronic acid, pamidronate, alendronate and risedronate) and receptor activators of nuclear factor kappa- Β ligand inhibitors (e.g., denosumab), are commonly used for treating osteoporosis, bone metastases, and other bone-related diseases. Side effects of Stevens–Johnson syndrome and toxic epidermal necrolysis in patients using N-BPshave been reported.1 In addition, maculopapular lesions,2 plaques an d ulcerations,3 dermatitides, and B-cell pseudolymphoma4 were reported in patients taking zoledronic acid. (Source: The American Journal of Medicine)
Source: The American Journal of Medicine - November 30, 2023 Category: General Medicine Authors: Sara Whitefield, Mor Bar Ilan, Towy Sorel Lazarovici, Silvina Friedlander-Barenboim, Riad Kassem, Yarom Noam Tags: Clinical Research Study Source Type: research
What is the role of risedronate in the primary and secondary prevention of fractures associated with osteoporosis in postmenopausal women? A Cochrane review summary with commentary
(Source: International Journal of Rheumatic Diseases)
Source: International Journal of Rheumatic Diseases - October 31, 2023 Category: Rheumatology Authors: Sina Arman Tags: COCHRANE CORNER Source Type: research
Clinicians ’ views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study
Bisphosphonate medications, including alendronate, ibandronate and risedronate administered orally and zoledronate, administered intravenously, are commonly prescribed for the treatment of osteoporosis based o... (Source: BMC Musculoskeletal Disorders)
Source: BMC Musculoskeletal Disorders - September 29, 2023 Category: Orthopaedics Authors: Simon Bishop, Melanie Jay Narayanasamy, Zoe Paskins, Nadia Corp, Anastasios Bastounis, Jill Griffin, Neil Gittoes, Jo Leonardi-Bee, Tessa Langley and Opinder Sahota Tags: Research Source Type: research
Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
Conclusion: According to this study, RIS-GR would be the dominant treatment (lower costs with QALY gain) compared with ALN.PMID:37712635 | DOI:10.57264/cer-2023-0115 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - September 15, 2023 Category: General Medicine Authors: Enrique Casado Jos é Rosas Carlos Rubio-Terr és Dar ío Rubio-Rodríguez Mitra Boolell Ignacio Ar ístegui Source Type: research
Oral Therapeutics Post Menopausal Osteoporosis
Cureus. 2023 Aug 2;15(8):e42870. doi: 10.7759/cureus.42870. eCollection 2023 Aug.ABSTRACTOsteoporosis affects a significant number of postmenopausal women in the United States. Screening is performed using clinical assessments and bone mineral density scans via dual x-ray absorptiometry. Oral therapy is indicated to prevent pathologic fractures in those deemed at increased risk following screening. Bisphosphonates including alendronate, ibandronate, and risedronate are currently first-line oral therapeutics in fracture prevention following the diagnosis of osteoporosis. Hormonal therapies include estrogen-containing therap...
Source: Pain Physician - September 4, 2023 Category: Anesthesiology Authors: Ryan J Schroeder Julia Staszkiewicz Collyn O'Quin Brandon Carroll Nicolette Doan Sagar Patel Shahab Ahmadzadeh Anusha Kallurkar Omar Viswanath Giustino Varrassi Sahar Shekoohi Alan D Kaye Source Type: research
Oral Therapeutics Post Menopausal Osteoporosis
Cureus. 2023 Aug 2;15(8):e42870. doi: 10.7759/cureus.42870. eCollection 2023 Aug.ABSTRACTOsteoporosis affects a significant number of postmenopausal women in the United States. Screening is performed using clinical assessments and bone mineral density scans via dual x-ray absorptiometry. Oral therapy is indicated to prevent pathologic fractures in those deemed at increased risk following screening. Bisphosphonates including alendronate, ibandronate, and risedronate are currently first-line oral therapeutics in fracture prevention following the diagnosis of osteoporosis. Hormonal therapies include estrogen-containing therap...
Source: Pain Physician - September 4, 2023 Category: Anesthesiology Authors: Ryan J Schroeder Julia Staszkiewicz Collyn O'Quin Brandon Carroll Nicolette Doan Sagar Patel Shahab Ahmadzadeh Anusha Kallurkar Omar Viswanath Giustino Varrassi Sahar Shekoohi Alan D Kaye Source Type: research
Can locally applied risedronate be an effective agent when combined with xenografts? An animal study
To examine the effects of local risedronate application with xenografts on healing of rabbit skull defects using histological, histomorphometric, immunohistochemical, and three-dimensional radiological methods. (Source: BMC Oral Health)
Source: BMC Oral Health - July 24, 2023 Category: Dentistry Authors: Taha Özer, Vusala Guliyeva, Alper Aktaş, Emre Barış and Mert Ocak Tags: Research Source Type: research
11 years secular trend of the initiation of anti-osteoporosis medications and subsequent fractures in Taiwan: From 2008 to 2018
CONCLUSION: This study showed an immediate drop in AOMs prescription after the implementation of a new stricter reimbursement policy. It took 5 years to return the annual prescription number.PMID:37280138 | DOI:10.1016/j.jfma.2023.05.023 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - June 6, 2023 Category: General Medicine Authors: Tsung-Han Yang Chen-Yu Wang Shau-Huai Fu Ding-Cheng Chan Ho-Min Chen Jou-Wei Lin Chun-Feng Huang Jen-Jia Yang Chih-Hsing Wu Jawl-Shan Hwang Rong-Sen Yang Source Type: research
Constraining in reimbursement criteria and the adherence to anti-osteoporosis medications (AOMs) in Taiwan: Urbanization makes the difference
CONCLUSION: The implementation of new reimbursement criteria in 2011 was associated with increased adherence to AOMs and the increase was most apparent in high-urbanization areas.PMID:37271714 | DOI:10.1016/j.jfma.2023.05.012 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - June 4, 2023 Category: General Medicine Authors: Chen-Yu Wang Tsung-Han Yang Shau-Huai Fu Jawl-Shan Hwang Ho-Min Chen Jou-Wei Lin Chih-Cheng Hsu Yin-Fan Chang Chih-Hsing Wu Ding-Cheng Chan Rong-Sen Yang Source Type: research
Constraining in reimbursement criteria and the adherence to anti-osteoporosis medications (AOMs) in Taiwan: Urbanization makes the difference
CONCLUSION: The implementation of new reimbursement criteria in 2011 was associated with increased adherence to AOMs and the increase was most apparent in high-urbanization areas.PMID:37271714 | DOI:10.1016/j.jfma.2023.05.012 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - June 4, 2023 Category: General Medicine Authors: Chen-Yu Wang Tsung-Han Yang Shau-Huai Fu Jawl-Shan Hwang Ho-Min Chen Jou-Wei Lin Chih-Cheng Hsu Yin-Fan Chang Chih-Hsing Wu Ding-Cheng Chan Rong-Sen Yang Source Type: research
Interrelations between clinical-psychological features and bone mineral density changes in post-menopausal women undergoing anti-osteoporotic treatment: a two-year follow-up
DiscussionThe findings of the current follow-up study suggest that BMD in post-menopausal women undergoing anti-osteoporotic treatment was predicted by treatment adherence and anxiety change over time. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - May 9, 2023 Category: Endocrinology Source Type: research
Refracture risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter
CONCLUSION: In addition to fracture prevention, anti-osteoporotic treatments for patients with vertebral fractures were associated with a reduction in mortality. A longer duration of treatment and the use of long-acting drugs was also associated with lower mortality.PMID:37120337 | DOI:10.1016/j.jfma.2023.04.004 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - April 29, 2023 Category: General Medicine Authors: Ta-Wei Tai Yi-Lun Tsai Chien-An Shih Chia-Chun Li Yin-Fan Chang Chun-Feng Huang Tien-Tsai Cheng Jawl-Shan Hwang Tsung-Hsueh Lu Chih-Hsing Wu Source Type: research
